Clinical trial
Orismilast for the Treatment of Mild to Severe Hidradenitis Suppurativa (OSIRIS)
NCT04982432 is registered in ClinicalTrials.gov with Gregor Jemec as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Orismilast for the Treatment of Mild to Severe Hidradenitis Suppurativa (OSIRIS)
- Lead sponsor
- Gregor Jemec
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- October 1, 2021
- Completion date
- December 1, 2022
- Enrollment
- 24 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.